Meeting
2023 ASCO Annual Meeting
Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.
Authors
Stéphane De Botton
Institut Gustave Roussy, Paris, France
Stéphane De Botton , Pau Montesinos , Susana Vives Polo , Ewa Zarzycka , Jianxiang Wang , Marta Riva , Michael Heuser , Rodrigo T. Calado , Andre C. Schuh , Su-Peng Yeh , Jianan Hui , Diego A. Gianolio , Prapti Arvind Patel , Christian Recher , Hartmut Dohner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT03173248
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7012)
DOI
10.1200/JCO.2023.41.16_suppl.7012
Abstract #
7012
Poster Bd #
142
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Hematologic improvements with ivosidenib + azacitidine compared to placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia.
First Author: Hartmut Dohner
Poster
2022 ASCO Annual Meeting
Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.
First Author: Stéphane De Botton
Poster
2021 ASCO Annual Meeting
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.
First Author: Curtis Andrew Lachowiez
Poster
2021 ASCO Annual Meeting
Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.
First Author: Scott N. Gettinger